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The complexity and heterogeneity of patients with multimorbidity and polypharmacy renders traditional disease-oriented guidelines often inadequate and complicates clinical decision making. To address this challenge, guidelines have been developed on multimorbidity or polypharmacy. To systematically analyse their recommendations, we conducted a systematic guideline review using the Ariadne principles for managing multimorbidity as analytical framework. The information synthesis included a multistep consensus process involving 18 multidisciplinary experts from seven countries. We included eight guidelines (four each on multimorbidity and polypharmacy) and extracted about 250 recommendations. The guideline addressed (i) the identification of the target population (risk factors); (ii) the assessment of interacting conditions and treatments: medical history, clinical and psychosocial assessment including physiological status and frailty, reviews of medication and encounters with healthcare providers highlighting informational continuity; (iii) the need to incorporate patient preferences and goal setting: eliciting preferences and expectations, the process of shared decision making in relation to treatment options and the level of involvement of patients and carers; (iv) individualized management: guiding principles on optimization of treatment benefits over possible harms, treatment communication and the information content of medication/care plans; (v) monitoring and follow-up: strategies in care planning, self-management and medication-related aspects, communication with patients including safety instructions and adherence, coordination of care regarding referral and discharge management, medication appropriateness and safety concerns. The spectrum of clinical and self-management issues varied from guiding principles to specific recommendations and tools providing actionable support. The limited availability of reliable risk prediction models, feasible interventions of proven effectiveness and decision aids, and limited consensus on appropriate outcomes of care highlight major research deficits. An integrated approach to both multimorbidity and polypharmacy should be considered in future guidelines.
Keywords: continuity of patient care, multimorbidity, older adults, patient-centred care, polypharmacy, practice guideline.
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Background
Family physicians care for patients with multiple conditions, known as multimorbidity [1] , in up to 80% of their consultations [2] , whilst in geriatrics this is the case for essentially all patients. The presence of multiple conditions makes the patient's management challenging in a number of ways. First, the potentially complex interlinked pathophysiological pathways underlying the conditions need to be taken into account in diagnosis and monitoring. Secondly, when developing care plans for these patients, the potential risks and benefits of interventions need to be taken into account both for each condition and across diseases. Furthermore, some concurrent conditions may not necessarily have a clinical impact but may complicate interpretation of symptom presentations. All this makes the process more difficult and the outcomes less certain [3] .
Patients with multiple conditions commonly take multiple prescriptions (polypharmacy) [4] , which further increase complexity. Firstly, by increasing the potential for interactions between diseases and treatments medication choice is less straightforward. Secondly, by increasing the possibility that additional medications will be prescribed to counteract side effects prescribing cascades may occur. Physicians involved in caring for these patients report that current decision support is inadequate to optimize benefits and minimize harms in these patients with complex needs [5] .
More than a decade ago, attention was drawn to the fact that the application of individual diseaseoriented guidelines to patients with multimorbidity was not feasible and potentially harmful [6] . In addition to the potential harm from interactions between diseases and treatments, there is also an often unrecognized treatment burden [7, 8] . However, other studies indicate that adherence to clinical practice guidelines has the potential to improve outcomes for a range of chronic conditions including chronic heart failure and COPD, which commonly occur in people with multimorbidity [9] [10] [11] [12] [13] .
Current approaches to support clinical decision making in multimorbidity and polypharmacy tend to adapt condition-specific guidelines to take into account co-occurring problems; or to present principles on how to make a conscious use of diseaseoriented guidelines [14] [15] [16] . More recently, clinical practice guidelines for the management of multimorbidity and polypharmacy have been developed [17] . However, questions arise whether these guidelines provide relevant support for clinical decision making considering the vast heterogeneity of diseases, their potential combinations and varying degrees of disease severity in these patients.
We therefore aimed to identify and analyse available evidence-based clinical practice guidelines for multimorbidity or polypharmacy in order to investigate the clinical decision support they provide and the key concepts they address. To facilitate the interpretation and actionability of the findings, we used the previously published Ariadne principles [15] , which provide a framework to guide care delivery in patients with multimorbidity. At the core, the sharing of realistic treatment goals by physicians and patients results from (i) an interaction assessment, that is, the thorough assessment of diseases and treatments including their potential interactions, the patient's clinical status, their context as well as a consideration of treatment burden; (ii) the prioritization of health problems taking into account the patient's preferenceshis or her most and least desired outcomes; and (iii) an individualized management plan which outlines the best options of care in diagnostics, treatment, and prevention to achieve the goals; (iv) goal attainment is followed-up with a re-assessment in planned visits and (v) the occurrence of new or changed conditions, such as an increase in severity, or a changed context may trigger a reevaluation of the previous steps [15] .
Methods
We conducted a modified systematic guideline review [18] followed by a workshop-based consensus meeting with multidisciplinary experts from North America and Europe.
Literature search and selection
We conducted a systematic search for existing clinical practice guidelines in the electronic databases MEDLINE, The Cochrane Library, Health Services/Technology Assessment Texts (HSTAT), 'Turning Research Into Practice' (TRIP) and Guideline International Network (G-I-N) database, as well as in the National Guideline Clearinghouse combining controlled terms and free text words, such as comorbidity, multimorbidity, multiple conditions, polypharmacy, multiple drugs, multiple medications and older adults. We conducted the searches in February and March 2018, dated back to the database inception. In addition, we searched websites of guideline producing organizations including geriatric and primary care societies (the complete list is provided in Appendix S1).
We included comprehensive guidelines or guideline-like documents on multimorbidity and polypharmacy, if they were 'systematically developed statements to assist practitioner and patient decisions about appropriate health care for specific clinical circumstances' [19] , if their purpose was 'to make explicit recommendations with a definite intent to influence what clinicians do' [20] and if they were endorsed by guideline producing organizations or physicians' colleges. We accepted definitions of multimorbidity and polypharmacy used in individual guidelines and no language restriction was applied. We excluded diseaseoriented guidelines (e.g. on osteoporosis management in elderly), guidelines with a narrow focus (e.g. on deprescribing of potentially inappropriate medications in the elderly, using specific indicators such as Beers criteria [21] ) or which did not report any methods of systematic development (a systematic literature search for at least some of the addressed questions had to be reported). Searches and selection of guidelines were conducted by two independent reviewers (AIGG and TSN).
Quality appraisal
We (AIGG, MSB, JWB and TSN) appraised the quality of the guidelines using the MiChe Checklist [22, 23] , which consists of eight specific questions (recommendations, audience, objectives, conflict of interest, systematic search, unambiguity, evaluation of benefits, and update) and two holistic items (overall assessment and recommendation for further use). Each specific question is answered as 'Yes', 'No' or 'To some extent', the overall assessment is rated on a Likert scale ranging from '1' = very poor to '7' = very good, and the recommendation is rated with 'Yes', 'Yes, with certain reservations' and 'No'.
Data extraction
We (AIGG, CM, JWB, MSB, TSN) extracted data from the guidelines according to a predefined framework based on the Ariadne principles [15] , which encompassed recommendations on (i) interaction assessment, (ii) prioritization of patient's preferences and agreement on shared treatment goals, (iii) individualized management of patients to achieve these goals and (iv) monitoring and follow-up of goal attainment. To fit the aim of the framework analysis, (v) ('trigger events' to (re)start the Ariadne principles) was reframed as methods for 'identification of the target population'.
Additional information on each guideline was extracted: the source, the year of publication, the country of origin, underlying concepts including definitions of multimorbidity and polypharmacy, the target setting, the target population and patient-related outcomes. For each topic of the a priori defined Ariadne framework, we (AIGG, CM, JWB, MSB, TSN) extracted the data into evidence tables using a standardized format, which included recommendation(s), level of evidence (LoE) and grade of recommendation (GoR) as provided in the guideline. When recommendations addressed more than one domain of the framework, we (CM, JWB) agreed upon the domain that best matched the recommendation to avoid duplicates.
Analysis
The numbers of recommendations per topic and per guideline were described. We (AIGG, CM, JWB, SMS, TSN) conducted a thematic analysis, assigned categories and aggregated the recommendations as outlined above using the Ariadne framework.
Expert consensus process
We discussed the results of the thematic synthesis at a 2-day meeting in May 2018. This meeting included a symposium, in which the background to the topic was elucidated and a workshop with 18 invited multidisciplinary experts -some of them with more than one area of expertise: geriatrics (7), primary care (6), public health and health services research (5), epidemiology (4) and pharmacy/pharmacology (2) from seven countries [Sweden (5), UK (4), USA (3), Italy and the Netherlands (2), Germany and Ireland (1)]. The group discussion was audio-recorded and transcribed and served as triangulation of the thematic analysis. The results of the guideline review and the group discussion were agreed upon and synthetized by all authors.
Results
In total, we included eight guidelines, four on multimorbidity and four on polypharmacy [24] [25] [26] [27] [28] [29] [30] [31] ( Fig. 1 ; the list of excluded guidelines with reasons for exclusion is provided in Appendix S2). Three guidelines were developed in the UK, two in Germany and one each in the USA, the Netherlands and Mexico (Table 1 [ 32, 33] ). Four guidelines were of very good quality, the remaining had minor shortcomings -mainly due to a limited reporting quality, including two which did not report on update procedures and therefore scored lowest in that domain (for details of the quality appraisal see Appendix S3).
In total, we extracted 246 recommendations [median: 27 recommendations per guideline (IQR: 13-52, range: 7-57)]. The most common recommendations addressed the need for a thorough assessment of interactions and individualized management of patients (n = 69 recommendations each), followed by identifying patient's preferences and goal setting (n = 50), monitoring and follow-up (n = 32), and identification of the target population (n = 26; Fig. 2 ). Some of the recommendations were not specific to a single domain, for example, recommendations on individualized management also incorporated elements of monitoring and follow-up.
Identification of the target population
In one guideline, a systematic search for existing risk predicting models revealed many models for patients with multimorbidity but not for patients with polypharmacy [28] . This guideline recommended the identification of adults with multimorbidity at risk of adverse events (e.g. unplanned hospital admission or admission to a care home) using prognostic models -either opportunistically during routine care or proactively using the electronic medical record (EMR) [28] . Five guidelines provided information about risk factors for negative health outcomes covering different dimensions, such as condition, medication, adherence-related, and risks related to social context and healthcare utilization [25, 26, [28] [29] [30] . Condition-related risk factors included the presence of certain chronic diseases such as depression, dementia or cognitive decline, combinations of chronic mental and physical diseases such as diabetes and schizophrenia, the presence of conditions or events such as frailty, falls, nonspecific symptoms and a worsening of health [25, [28] [29] [30] . Medication-related risks referred to drugs with a narrow therapeutic range, high potential for drug-drug interactions, the need for constant monitoring, psychotropic drugs and where patients received a suboptimal benefit from pharmaceutical treatment [26, 29] . Patients with nonadherence, difficulties managing their treatment regimen due to a high treatment burden or administration problems were also regarded as being at risk [25, 28, 29] . Social risk factors included problems managing day-to-day activities, not living independently, limited ability to understand treatment recommendations (e.g. language problems and health literacy), advanced age and limited access to health care [25, [28] [29] [30] . The involvement of multiple and uncoordinated healthcare professionals and low uptake of care plans was noted to increase unplanned hospital admissions and emergency care [25, 28, 29] .
Interaction assessment
According to the Ariadne Principles, the interaction assessment should be conducted as a thorough assessment of diseases (including severity and impact on quality of life and functioning) and treatments (including potential interactions, adverse drug reactions, underuse and adherence), and of the clinical status and psychosocial context of the patient [15] . Seven guidelines addressed this principle, covering the medical history, a clinical and psychosocial assessment, a medication review and consideration of previous health services utilization [25] [26] [27] [28] [29] [30] [31] . Regarding the medical history, the documentation of all known diagnoses and conditions as well as existing laboratory test results and medication-related problems in the electronic medical record was recommended [25, 29] . One guideline [25] recommended the use of a structured questionnaire [34] about medication use, problems,
Box 1. Key recommendations on interaction assessment
Guiding principles
• Assess diseases, health problems, clinical and functional status, pharmacological and nonpharmacological treatment including potential interactions between diseases and treatments as well as the burden for the patient and take into account his/her psychosocial context [25] [26] [27] [28] [29] [30] [31] .
• Involve patients and their family members or carers, where appropriate, in the assessment process, and clarify and resolve misconceptions [26, 31] .
• Explore patient's contacts with other healthcare professionals and any related changes in management and consider using information technology support and a multidisciplinary team-based approach [26, 28, 29, 31] .
Specific recommendations on clinical management
• Clinical assessment: Assess the management of health problems such as chronic pain, depression and anxiety, the presence of incontinence, the physiological and functional status and whether there are nutritional and hydration requirements [27, 28] .
• Medication review: Evaluate the risk benefit of each drug, its possible interactions and adverse effects, adherence to treatment and unmet needs and be aware of possible prescribing cascades [29, 30] . Assess the use of prescriptions, over-the-counter and food supplements or medicinal herbs and the actual implementation of a medication plan [29, 30] . Undertake a medication review regularly once a year; more often if needed, for example in relation to hospital stays: on admission, transfers between wards and at discharge [27, 29] . Use multiple methods such as health record reviews, patient surveys during consultations in practice or home visits and direct observation of medicines administration [26] [27] [28] [29] .
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• Discuss with the person the purpose of the approach to care, for example, to improve quality of life and function. This might include reducing treatment burden and optimizing care and support by identifying possible improvements in medication and reducing inappropriate or medication with negative effect [28] .
• The process of eliciting patient preferences requires several steps: 1) recognize when the patient with multimorbidity is facing a 'preference sensitive' decision; 2) ensure patients with multimorbidity are adequately informed about the expected benefits and harms and 3) elicit patient preferences only after the individual with multimorbidity is sufficiently informed [24] .
• Explore patient's expectations and objectives about treatments before prescribing [29] .
• Find out what level of involvement in decision making the person would like and avoid making assumptions about this [26] .
• Use the best available evidence when making decisions with or for individuals, together with the clinical expertise and the person's values and preferences [26] .
Specific recommendations on self-management support
• Encourage patients with multimorbidity to clarify what is important to them, including
Specific recommendations on self-management support †
• Establish disease and treatment burden, its effect on day-to-day life including mental health, general wellbeing and quality of life [28] . Establish additional burden arising from caring responsibilities [27] . These features need to be incorporated when considering patients' capacity and the supports needed for self-management of long-term conditions and treatments [27] .
Toolbox
Clinical assessment
• Instruments determining patient capacity and vulnerability to interactions, such as gait speed, self-reported health status, the PRISMA-7 questionnaire [35] (primary care), the 'Timed Up and Go' test [36] , the Physical Activity Scale for the Elderly [37] (hospital outpatients) and Comprehensive Geriatric Assessment, CGA [38] (hospitals).
Medication assessment
• Instruments based on implicit criteria, such as MAI (Medication Appropriateness Index) [39] , ACOVE (Assessing Care of Vulnerable Elders) [40] , and the STRIP method (Systematic Tool to Reduce Inappropriate Prescribing) [28] .
• Instruments based on explicit criteria, such as Recommendations on a medication review were at the core of the included polypharmacy guidelines, but were also addressed in the multimorbidity guidelines. One of them stressed the importance of informational continuity, to explore encounters with other physicians or healthcare professionals and changes in management over time [29] (Box 1).
Patient's preferences, prioritization and goal setting
All but one of the guidelines provided recommendations on eliciting patient preferences and expectations, including guidance on the level of involvement of patients and carers. The recommendations also focus on the process of shared decision making in relation to treatment options and the way they are communicated [24] [25] [26] [27] [28] [29] 31] . Two guidelines provided specific recommendations regarding decision aids as tools to support shared decision making [26, 28] . Additionally, one guideline referred to the need for specific skills and expertise in the use of patient decision aids [26] (Box 2).
Individualized management
All guidelines provided recommendations on this topic. Guiding principles referred to the optimization of treatment benefits over possible harms in pharmaceutical and nonpharmaceutical interventions. They also referred to information that should be included in medication plans -and, in wider care plans, including social and tele-health care [24, [26] [27] [28] [29] [30] . Recommendations on treatment communication (with or without direct consideration of selfmanagement support) were a strong focus in four guidelines [26] [27] [28] [29] , and the coordination of care was addressed in more than half of guidelines [24, [26] [27] [28] [29] 31] . Self-management support was addressed indirectly in relation to individualized management
Box 3. Key recommendations on individualized management
• Use strategies for choosing therapies that optimize benefit, minimize harm and enhance quality of life for patients with multimorbidity and consider treatment burden, complexity and feasibility [24, 28] .
• Consider the applicability and quality of evidence such as study population, study duration, benefits in terms of absolute risk reduction and time horizon. Studies in younger patients without multimorbidity and polypharmacy and with short follow-up times and relative risk reduction may overestimate benefits and underestimate harms, and time horizon to benefit may be too late to achieve relevant treatment effects in older patients with multimorbidity and polypharmacy [24, 28, 30] .
• In deprescribing medication(s), follow a systematic approach including identification and prioritization of medicines to be discontinued, stopping one at a time and consideration of tapering dosage rather than stopping, and planning and communicating with patients (and caregivers, if necessary) [29] .
• Ensure care plans are tailored to each person, giving them choice and control and recognizing the inter-related nature of multiple longterm conditions [27] .
• Health professionals involved in the treatment of patients with multimorbidity should share relevant information about the person and their medicines -in particular when patients are transferred to another care setting [27, 31] .
Specific recommendations on clinical management
• Be aware that the management of risk factors for future disease can be a major treatment burden for people with multimorbidity and should be carefully considered when optimizing care [28] .
their personal goals, values and priorities [28] .
Toolbox
• Use a patient decision aid to help them make a preference sensitive decision that involves trade-offs between benefits and harms, if available in high quality and appropriate in the context of the consultation as a whole [26] .
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in half of the guidelines [26] [27] [28] [29] . The guidelines which addressed this issue focused primarily on self-management support for medicines management and support with care coordination (Box 3).
Monitoring and follow-up
In five guidelines, aspects of follow-up and monitoring of treatment effects as well as goal attainment were addressed [25] [26] [27] [28] [29] . Recommendations covered strategies in care planning, self-management and medication-related aspects, the communication with patients including patient information and safety instructions as well as adherence, the coordination of care regarding medication appropriateness and safety concerns, possible collaboration with pharmacies, the involvement of care coordinators, referrals and discharge management [25] [26] [27] [28] [29] . Additionally, organizational or healthcare professionals' responsibilities with regard to follow-up of medication-related aspects and the specific conditions in care homes were addressed in two guidelines [26, 27] (Box 4).
Discussion

Summary of included guidelines
Our review identified eight comprehensive guidelines addressing older patients with multimorbidity or polypharmacy. Many guidelines had to be excluded, mainly due to a lack of reporting of systematic search strategies. The vast majority of
• When prescribing medications such as statins and bisphosphonates, be aware that they may only provide benefit to elderly patients who have estimated survival greater than five years [30] .
• The selection of a primary pharmacy is recommended to support the coordination of self-administered drugs with regard to dosage instructions and overall medication regimens, particularly when there are multiple prescribers [29] .
• Ensure there is community-based multidisciplinary support for patients with multimorbidity with social care needs which might include, for example, a physiotherapist or occupational therapist, a mental health social worker or psychiatrist and community-based services [27] .
Specific recommendations on self-management support
• Consider using an individualized patient-held medication plan that should include information on drugs and specific instruction for usage; if dosage is 'as needed', exact information about indication and individual dosage must be provided (single dose, interval and maximal daily dosage); in short-term prescriptions, the prospective end date should be specified and information about medication history and reduced renal function should be included when indicated [29] .
• Develop care plans that address ongoing medical and social care needs for individual patients that focus on enhancing social connectedness and community involvement and also ensuring that carers' needs are taken into consideration and that these care plans do not add to treatment burden [26] [27] [28] .
• Ensure ongoing and adequate communication, in particular around medicines and wider care plans with identification of perceived benefits and ensuring patient involvement in the process [26] [27] [28] .
• Consider with the person whether there are tele-healthcare options that may support them to make informed choices to help them manage their conditions, as well as other potential benefits, risks and costs [27] .
• Consider the use of named care coordinators who can agree a course of action with patients and their carers if these needs cannot be addressed by existing health and social care professionals. This may be particularly important at times of transition, for example when considering moving to a care home [27] .
Toolbox
• Computerized decision support systems (CDSS) that support decision making and prescribing but do not replace clinical judgment; and options for tele-health care [26, 27] .
the included guidelines were of good quality according to the MiChe checklist [22, 23] . Interestingly, only three of eight guidelines used levels of evidence and grades of recommendations, despite the recognition of their importance [48] . This may reflect the fact that evidence for effective interventions in this population is scarce and that expert consensus may often represent the best available evidence. However, this has also been the case for disease-specific guidelines. For example, in chronic heart failure, a review found that about half of the guideline recommendations were consensus based [18] . There is a clear need to prioritize research to generate evidence for effective interventions in 'real-world patients'.
The recommendations included in the guidelines covered a broad spectrum of aspects related to clinical management and self-management and included recommendations beyond traditional realms of clinical guidelines (e.g. regarding structural requirements of organizations, knowledge and skills of different care providers). The recommendations varied in their specificity -from abstract guiding principles to detailed specific recommendations on necessary changes in practice and which tools may provide actionable support. Multimorbidity guidelines more often provided generic guiding principles, whereas those addressing polypharmacy tended to provide more specific recommendations and tools, but both remarkably neglected cognitive dysfunction. This is surprising for a frequent problem in this population, and one that is frequently underdiagnosed and has a major impact on health status and • Review and update medication/care plans regularly to recognize and record changes in needs [25] [26] [27] [28] [29] .
Specific recommendations on clinical management
• • Monitor treatment after discharge: due to the (usually) short duration of a hospital stay, newly introduced medications may not have reached steady state at discharge, because inpatient care is frequently shorter than 4 to 5 half-lives of prescribed drugs. Effectiveness and side effects cannot necessarily be properly assessed in hospital [29] .
• Monitor ongoing treatment including demonstrations of medication administration (e.g. inhalers) and effective forms of self-monitoring [29] .
• Consider continuing to offer information and support to people and their carers, even if they have declined this previously, recognizing that long-term conditions can be changeable or progressive, and people's information needs may change [26] .
• Review the self-management plan to ensure the person does not have problems using it [26] .
• Health and social care providers should explain to patients, and their family members or carers where appropriate, how to identify and report medicines-related patient safety incidents that arise during follow-up periods [26] .
• Self-management plans could include specific arrangements about follow-up to review the decisions made [28] .
ª 2018 The Association for the Publication of the Journal of Internal Medicine 283 significant implications for self-management and interference with the health care system [49] . Furthermore, recommendations about pharmacologic treatment outweighed other types of recommendations (e.g. physical exercise) and no guideline specifically provided decision support for screening or diagnostic procedures. The impact of multimorbidity on diagnosis is not trivial as it can affect diagnostic accuracy and cause diagnostic delay with important implications for prognosis [50, 51] .
The elicitation and consideration of patient preferences were considered as an essential part of the management of patients with multimorbidity and polypharmacy by all included guidelines. Caution was recommended in the use of decision aids because they were mainly developed for single diseases. It is noteworthy, that only three guidelines involved patient representatives in the development process.
Barriers and facilitators to implementation of recommendationsmodels of care
A major barrier to implementation is that current healthcare models are based on the single disease paradigm, with the exceptions of certain settings (primary care) and specialties services (geriatrics, mental health). Guideline recommendations generally did not account for settings, with the exception of differentiated recommendations on instruments that can assist a clinician in determining patient functional capacity. For example, the comprehensive geriatric assessment has been shown to be effective in hospitals [38] but not in primary care [52] . Geriatricians and family physicians, whilst sharing a holistic approach, typically operate under different frameworks. Geriatricians are more often based in hospitals and provide care for the 'geriatric patient', whilst family physicians provide longitudinal care for unselected patients [53] [54] [55] . This has important implications in primary care, for example, in the organization of long-term follow-up and monitoring but also in the identification of patients with multimorbidity and polypharmacy who are at risk of developing negative health outcomes -that is to differentiate between the 'fit and active' and people in need for an intensified care approach [28] . Research is needed that supports reliable methods for ensuring that those most at risk of adverse events are identified and benefit from appropriate interventions.
The complexities associated with the management of multimorbidity and polypharmacy make it advisable to ensure the involvement of other health and Clinical management of multimorbidity and polypharmacy / C. Muth et al.
social care professionals for patients with low health literacy or a complex social background. Multi-professional care teams including social workers -and in certain countries, care coordinators-may facilitate the implementation of recommendations if a context-specific tailoring of the recommendations is warranted.
Guidelines recommend clinicians to encourage self-management but the evidence for specific self-management support programs on multimorbidity is lacking [56] . Further research is needed on interventions that support priority setting and strategies to reduce barriers to selfmanagement.
Communication with patients
All guidelines emphasized the importance of communication with patients and their carers about the patient's needs, priorities and preferences for improving patient-centred health outcomes and minimizing the burden of care and overtreatment. Decision aids to support this communication process have been developed generally for single chronic diseases. Decisions about health care for patients with multimorbidity require a more individualized approach that considers outcomes across conditions, such as overall health related quality of life, functioning or symptom-free survival.
Patient's preferences for prioritized outcomes may shift over time [57] but also with regard to the alternatives [58, 59] . Repeated communication about the importance and prioritization of outcomes is therefore imperative. Instruments to communicate about prioritization and preferences with regard to outcomes have been developed, again mostly with a condition-specific approach [60] [61] [62] and limited psychometric properties [61] . Individual goal setting and prioritization are core tasks in individualizing the care for patients with multimorbidity. Although interventions have been developed to support this collaborative process between patients and clinicians, the evidence supporting their effectiveness is still lacking [56] . Which components of these often multifaceted interventions are most relevant is not clear [63] .
Guidelines on multimorbidity versus polypharmacy
Existing guidelines follow concepts on multimorbidity (diagnosis based) or polypharmacy (treatment based) but the issues raised are relevant to essentially the same patient population in clinical practice. Medication reviews, for example, were at the core of the polypharmacy and multimorbidity guidelines and the review itself must take into consideration both patient's conditions and treatments. The separate production of guidelines addressing either multimorbidity or polypharmacy seems arbitrary and their combination would also relieve the burden -for developers and users.
Limitations
The systematic guideline review method offers a transparent and comprehensive approach to the analysis of existing guidelines, but our in-depth text analysis may not be free from subjectivity with regard to the themes selected and presented in this review.
Concluding remarks
Our review identified eight comprehensive guidelines of good quality addressing older patients with multimorbidity or polypharmacy. The guideline recommendations covered a broad spectrum of aspects of clinical and self-management, beyond the realms of traditional disease-oriented guidelines. The recommendations varied in their specificity -from abstract guiding principles to detailed recommendations on necessary changes in practice and tools providing actionable support. The limited availability of reliable risk prediction models, feasible interventions of proven effectiveness and decision aids, as well as limited consensus on appropriate outcomes of care highlight major research deficits. An integrated approach to both multimorbidity and polypharmacy should be considered in future guidelines.
